Dr. Dwight Owen, MD
Claim this profileOhio State University Comprehensive Cancer Center
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
19 drugs studied
Area of expertise
1Lung Cancer
Global LeaderStage IV
EGFR positive
Stage I
2Non-Small Cell Lung Cancer
Stage IV
EGFR positive
Stage I
Affiliated Hospitals
Clinical Trials Dwight Owen, MD is currently running
Temozolomide + Atezolizumab
for Small Cell Lung Cancer
This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving temozolomide and atezolizumab as second or third line treatment may help prolong survival in patients with small cell lung cancer.
Recruiting1 award Phase 215 criteria
Atezolizumab + Chemotherapy
for Non-Small Cell Lung Cancer
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy. However, relapse rates remain high and are primarily due to distant, metastatic disease. Previous meta-analysis evaluating the use of neo-adjuvant chemotherapy and adjuvant chemotherapy demonstrate a similar impact on improved disease free survival (DFS) and overall survival (OS). The role of checkpoint inhibitors has been proven to be effective in the treatment of patients with advanced NSCLC, regardless of histology and PD-L1 expression. Results from trials evaluating the use of checkpoint inhibitors alone or in combination with chemotherapy in the neoadjuvant setting for early stage disease are promising. However, there are no trials evaluating the role of concomitant chemotherapy and checkpoint inhibitors in the adjuvant setting. In addition, emerging data supports the use of ctDNA as a promising biomarker for early detection of minimal residual disease and have indicated that the presence of detectable ctDNA after surgery for localized lung cancer is correlated with a 90-100% chance for disease recurrence. Therefore, we propose this current study assessing concomitant chemotherapy plus Atezolizumab in the adjuvant setting for patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC who have detectable ctDNA after surgery. The clearance of ctDNA will serve as a surrogate for long term DFS and OS in this patient population.
Recruiting1 award Phase 212 criteria
More about Dwight Owen, MD
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Dwight Owen, MD has experience with
- Atezolizumab
- Pembrolizumab
- Carboplatin
- Temozolomide
- Vismodegib
- Nivolumab
Breakdown of trials Dwight Owen, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Skin Cancer
Solid Tumors
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dwight Owen, MD specialize in?
Dwight Owen, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are EGFR positive.
Is Dwight Owen, MD currently recruiting for clinical trials?
Yes, Dwight Owen, MD is currently recruiting for 7 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Dwight Owen, MD has studied deeply?
Yes, Dwight Owen, MD has studied treatments such as Atezolizumab, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Dwight Owen, MD?
Apply for one of the trials that Dwight Owen, MD is conducting.
What is the office address of Dwight Owen, MD?
The office of Dwight Owen, MD is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.